Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention
AuthorKaya, Mehmet Güngör
MetadataShow full item record
Elevated uric acid (UA) levels have been associated with cardiovascular disease in epidemiologic studies. The relation between UA levels and long-term outcomes in patients with ST-segment elevation myocardial infarction who undergo primary percutaneous coronary intervention is not known. Data from 2,249 consecutive patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention were evaluated. Patients were divided into 2 groups with high or low UA using upper limits of normal of 6 mg/dl for women and 7 mg/dl for men. There were 1,643 patients in the low-UA group (mean age 55.9 +/- 11.6 years, 85% men) and 606 patients in the high-UA group (mean age 60.5 +/- 12.6 years, 76% men). Serum UA levels were 8.0 +/- 1.5 mg/dl in the high-UA group and 5.2 +/- 1.0 mg/dl in the low-VA group (p < 0.001). The in-hospital mortality rate was significantly higher in patients with high UA levels (9% vs 2%, p < 0.001), as was the rate of adverse outcomes in patients with high UA. The mean follow-up time was 24.3 months. Cardiovascular mortality, reinfarction, target vessel revascularization, heart failure, and major adverse cardiac events were all significantly higher in the high-UA group. In a multivariate analyses, high plasma UA levels were an independent predictor of major adverse cardiac events in the hospital (odds ratio 2.03, 95% confidence interval 1.25 to 3.75, p = 0.006) and during long-term follow-up (odds ratio 1.64, 95% confidence interval 1.05 to 2.56, p = 0.03). In conclusion, high UA levels on admission are independently associated with in-hospital and long-term adverse outcomes in patients with ST-segment elevation myocardial infarction who undergo primary percutaneous coronary intervention.